Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-51,159,048
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 464,747
- Avg volume
- 86,652
- Day's range
- $0.03 – $0.04
- Shares out
- —
- Stochastic %K
- 36%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiar...
Show more
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
- Phone
- 416-477-1708
- Website
- https://psyencebiomed.com
- Address
- 121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada
Latest news
No headlines yet.
